A Randomized Trial of Loading Vancomycin in the Emergency Department

Annals of Pharmacotherapy

Volumn 49, Issue 1, 2015, Pages 6-13

  Rosini, Jamie M ^a   Laughner, Julie ^a   Levine, Brian J ^a,b   Papas, Mia A ^c   Reinhardt, John F ^a   Jasani, Neil B ^a,b  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF DELAWARE   (United States)

Author keywords

emergency department; pharmacokinetics; trough; vancomycin

Indexed keywords

ANTIHISTAMINIC AGENT; CREATININE; HYDROMORPHONE; LACTIC ACID; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; FLUSHING; HUMAN; INJECTION SITE INFECTION; INTENTION TO TREAT ANALYSIS; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NEPHROTOXICITY; PNEUMONIA; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN INFECTION; STEADY STATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; AGED; DOSE RESPONSE; EMERGENCY HEALTH SERVICE; MIDDLE AGED; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AGED; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84919608313     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014556813     Document Type: Article

References (19)

1. Rybak M,Lomaestro B,Rotschafer JC, et al.Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.Am J Health Syst Pharm. 2009;66:82-98
2. Rybak M,Lomaestro B,Rotschafer JC, et al.Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Disease Pharmacists.Clin Infect Dis. 2009;49:325-327
3. Kullar R,Davis SL,Levine DP,Rybak MJ.Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.Clin Infect Dis. 2011;52:975-981
4. Lodise TP,Graves J,Evans A, et al.Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.Antimicrob Agents Chemother. 2008;52:3315-3320
5. Rybak MJ.The pharmacokinetic and pharmacodynamic properties of vancomycin.Clin Infect Dis. 2006;42:S35-S39
6. Craig WA.Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.Clin Infect Dis. 1998;26:1-12
7. Moise-Broder PA,Forrest A,Brimingham MC,Schentag JJ.Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.Clin Pharmacokinet. 2004;43:925-942
8. Kullar R,Davis SL,Taylor TN,Kaye KS,Rybak MJ.Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.Pharmacotherapy. 2012;32:195-201
9. Sakoulas G,Gold HS,Cohen RA,Venkataraman L,Moellering RC,Eliopoulos GM.Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteremia.J Antimicrob Chemother. 2006;57:699-704
10. Diggle PJ,Heagerty P,Liang K-Y,Zeger SLAnalysis of Longitudinal Data. 2nd ed.Oxford, UK: Oxford University Press; 2002.Oxford, UK: Oxford University Press; 2002:
11. Snijders T,Bosker RMultilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling. London, UK: Sage; 1999:
12. Diez-Roux AV.Multilevel analysis in public health research.Annu Rev Public Health. 2000;21:171-192
13. Liang KY,Zeger SL.Longitudinal data analysis using generalized linear models.Biometrika. 1986;73:13-22
14. Hardin JW,Hilbe JMGeneralized Estimating Equations. Boca Raton, FL: Chapman & Hall/CRC; 2003:
15. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP; 2011:
16. Soto J,Sacristan JA,Alsar MJ.Necessity of a loading dose when using vancomycin in critical-ill patients.J Antimicrob Chemother. 1991;27:875
17. Wang JT,Fang CT,Chen YC,Chang SC.Necessity of a loading dose when using vancomycin in critically ill patients.J Antimicrob Chemother. 2001;47:246
18. Lodise TP,Patel N,Lomaestro BM,Rodvold KA,Drusano GL.Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.Clin Infect Dis. 2009;49:507-514
19. Cano EL,Haque NZ,Welch VL, et al.Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database.Clin Ther. 2012;34:149-157